Medical Marijuana for Complex Regional Pain Syndrome (CRPS) in Ohio

Complex regional pain syndrome is one of the most treatment-resistant chronic pain conditions recognized under Ohio’s medical marijuana qualifying list — and one where a genuinely unique biological connection to the endocannabinoid system has been documented in the research. For Ohio CRPS patients whose pain has not responded adequately to first-line treatments, this page explains how the condition qualifies, what the research shows, and how to approach the evaluation.

Does CRPS Qualify for Medical Marijuana in Ohio?

Yes. Complex regional pain syndrome qualifies under Ohio’s medical marijuana program. As formally determined by the State Medical Board of Ohio, CRPS is recognized as qualifying under Ohio’s chronic and severe or intractable pain category — the same broad qualifying framework established in Ohio Revised Code Section 3796.01.

A physician holding a Certificate to Recommend (CTR) issued by the State Medical Board evaluates whether your documented CRPS diagnosis and symptom picture support a medical marijuana recommendation. Ohio law does not restrict the chronic pain qualifier to specific pain conditions by name — the evaluation focuses on whether your pain is chronic and severe or intractable and how it has responded to prior treatment.

What Is CRPS and Why Is It Particularly Relevant to Medical Marijuana?

Complex regional pain syndrome is a chronic neuropathic pain condition typically affecting the extremities — most often following a triggering injury, surgery, or trauma — characterized by severe burning pain, hypersensitivity, swelling, changes in skin temperature and color, and abnormal sweating. It is distinct from other pain syndromes by the presence of autonomic dysfunction and regional inflammatory changes, and remains one of the most difficult chronic pain conditions to treat effectively.

As reviewed in a pharmacological treatment analysis published through PMC from researchers at the Cleveland Clinic and Peking Union Medical College, CRPS is a disabling condition with a prevalence of approximately 5.4 to 26.2 per 100,000 persons per year — and research spanning 30 years has produced extensive understanding of the condition while the underlying mechanism remains controversial.

What makes CRPS particularly relevant to medical marijuana research is a specific endocannabinoid finding. As reviewed in research published through PMC, researchers have found enhanced plasma levels of the endocannabinoid anandamide in CRPS patients — suggesting that the endocannabinoid system may already be upregulated in CRPS as a natural protective mechanism attempting to limit pain and inflammation. This biological finding provides a rationale for cannabinoid therapy in CRPS that goes beyond general pain management.

What Does the Research Show?

The First CRPS-Specific Clinical Outcomes Study — Published

The most significant recent development in CRPS cannabis research is a clinical outcomes analysis published through PMC using data from the UK Medical Cannabis Registry — representing the first analysis of clinical evidence specifically examining cannabis-based medicinal products in CRPS patients.

The case series assessed patient-reported outcome measures over six months in CRPS patients prescribed cannabis-based medicines. The study found that cannabis-based medicinal products were associated with improvements in pain severity and interference — with clinically important improvements in pain VAS scores particularly notable among patients with prior cannabis use. Health-related quality of life improvements were also observed, mirroring results from similar registry studies.

The researchers concluded that their findings support further research through high-quality randomized controlled trials to determine the efficacy of cannabis-based medicinal products in CRPS — and that 20% to 40% of CRPS patients experience pain refractory to first-line pharmacological therapies, making novel therapeutics urgently needed for this population.

Earlier Controlled Research on Cannabis and Neuropathic Pain

The broader neuropathic pain research base — which CRPS falls under — provides additional context. A systematic review published through PMC examining pharmacological treatments for CRPS specifically found that cannabis-based medicines could be an effective treatment option for CRPS patients based on available trial evidence — citing studies showing that both low-dose and medium-dose vaporized cannabis produced significant pain reduction greater than 30% compared to placebo.

Where the Evidence Stands — Honest Assessment

The same systematic review noted that current medical cannabis guidelines assign only weak recommendations for cannabinoids in non-cancer pain — recommending they be used as third or fourth line therapy only, after established treatments have been tried. This framing is important for Ohio CRPS patients to understand: medical marijuana is supported by the evidence as an option for refractory CRPS — meaning patients who haven’t responded to earlier lines of treatment — rather than as a first or second line approach.

Why CRPS Patients Are Among the Most Relevant Medical Marijuana Candidates

As stated in the UK Medical Cannabis Registry study, 20% to 40% of CRPS patients experience pain refractory to first-line pharmacological therapies. CRPS is routinely described in clinical literature as one of the most painful and treatment-resistant chronic pain conditions in existence — with some pain rating scales placing it at or near the highest scores of any documented painful condition.

For Ohio CRPS patients who have worked through physical therapy, nerve blocks, sympathetic blocks, medications including anticonvulsants, antidepressants, corticosteroids, and opioids without achieving adequate pain control — the refractory population described in the research — medical marijuana represents a physician-supervised option that the evidence base specifically identifies as relevant for this group. Our guide on comparing medical marijuana with traditional back pain treatments for Ohio patients covers the research comparison between cannabinoids and conventional pain treatments in more detail.

What Documentation Do Ohio CRPS Patients Need?

Ohio-certified physicians evaluating CRPS patients look for documentation that establishes the diagnosis and captures the treatment journey:

Physician or specialist records confirming your CRPS diagnosis — ideally from a pain specialist, neurologist, or rheumatologist using the Budapest diagnostic criteria which are the current standard for CRPS diagnosis. Treatment history documenting first and second line therapies tried — including medications, physical therapy, nerve blocks, sympathetic blocks, and any other interventions. Records showing how your pain has responded or failed to respond to prior treatment are particularly important for establishing the intractable pain pathway under Ohio law. Current medication list for the OARRS check — important given that CRPS patients often take multiple medications including anticonvulsants and opioids that may interact with cannabinoids.

Getting Your Ohio CRPS Medical Marijuana Evaluation

Ohio’s telemedicine evaluation is particularly practical for CRPS patients whose allodynia, hypersensitivity, and mobility limitations may make traveling to an in-person clinic not only difficult but potentially painful. The entire process is completed online — at the patient’s own pace and in their own environment.

After completing a short intake form, a brief video consultation of 10 to 20 minutes with an Ohio-certified physician covers your CRPS diagnosis, treatment history, and current medications. If approved, your recommendation is submitted directly to the Ohio Patient & Caregiver Registry and your digital card is activated via email — valid at any licensed Ohio dispensary statewide. There is no charge if the physician determines you do not qualify.

If you are an Ohio CRPS patient and want to find out whether you qualify for the medical marijuana program, you can schedule your evaluation here.

Frequently Asked Questions

Sources

• Ohio Revised Code Section 3796.01 — Qualifying Medical Conditions — Ohio Laws
• State Medical Board of Ohio — Covered Conditions — med.ohio.gov
• Ohio Patient & Caregiver Registry — Ohio Division of Cannabis Control
• UK Medical Cannabis Registry: Clinical Outcomes Analysis for CRPS — PMC / NIH
• Pharmacological Treatment in CRPS: Systematic Review and Meta-Analysis — Cleveland Clinic — PMC / NIH
• Symptom-Based to Mechanism-Based Pharmacotherapy in CRPS — PMC / NIH